Continuous Subcutaneous Insulin Infusion Market Size, Share, Growth, and Industry Analysis, By Type (Normal, Patch Pump), By Application (Hospital, Retail Pharmacy, Other), Regional Insights and Forecast to 2035

The Continuous Subcutaneous Insulin Infusion Market

The global Continuous Subcutaneous Insulin Infusion market size was valued at USD 7326.37 million in 2026 and is projected to grow from USD 17268.37 million in 2026 to USD 17268.37 billion by 2035, exhibiting a CAGR of 10% during the forecast period.

The Continuous Subcutaneous Insulin Infusion Market is expanding due to the increasing prevalence of diabetes and rising adoption of insulin pump technologies across healthcare systems. More than 537 million adults globally were living with diabetes in 2024, while over 38 million people in the United States were diagnosed with diabetes. Approximately 10% of diabetic patients have type 1 diabetes, a primary target population for continuous subcutaneous insulin infusion devices. Over 2 million insulin pump users were recorded globally in 2025, with wearable patch pumps accounting for nearly 38% of installations. Bluetooth-enabled insulin pumps represented over 45% of newly launched systems, while closed-loop integration adoption exceeded 32% among advanced diabetes management users worldwide.

The United States remains the largest market for continuous subcutaneous insulin infusion (CSII) systems, supported by a high prevalence of type 1 diabetes, expanding use of automated insulin delivery, and strong reimbursement pathways. More than 38 million Americans live with diabetes, while advanced insulin pump adoption continues to rise through integration with continuous glucose monitoring technologies. U.S.-based manufacturers are accelerating innovation with tubeless pumps, smartphone connectivity, and algorithm-driven dosing. Regulatory approvals and expanded pediatric indications have strengthened patient access, while partnerships between pump and sensor developers are improving interoperability and enabling more personalized diabetes management across hospitals and home-care settings.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 62% of type 1 diabetes patients prefer automated insulin delivery systems, while nearly 48% of insulin-dependent diabetic patients reported improved glucose stability through continuous subcutaneous insulin infusion devices and 37% experienced reduced hypoglycemic episodes.
• Major Market Restraint: Approximately 42% of patients identified high device maintenance expenses as a barrier, while 33% reported infusion-set complications, 26% experienced skin irritation, and nearly 19% discontinued pump therapy within the first 24 months of treatment initiation.
• Emerging Trends: Around 54% of newly launched insulin pumps now include smartphone connectivity, while 46% support artificial intelligence-based dosing algorithms, 39% include predictive glucose alerts, and 31% integrate with continuous glucose monitoring platforms automatically.
• Regional Leadership: North America accounts for nearly 44% of global Continuous Subcutaneous Insulin Infusion Market demand, while Europe contributes approximately 29%, Asia-Pacific holds 21%, and Middle East & Africa collectively represent nearly 6% of installed insulin pump systems.
• Competitive Landscape: More than 71% of global market penetration is controlled by the top 3 manufacturers, while patch pump producers account for nearly 28% of competitive shipments and integrated hybrid closed-loop systems represent approximately 49% of premium product installations.
• Market Segmentation: Normal insulin pumps account for approximately 63% of device utilization globally, while patch pumps contribute nearly 37%; hospital applications represent 41% of deployments, retail pharmacies account for 36%, and other healthcare channels contribute approximately 23%.
• Recent Development: During 2023-2025, more than 14 advanced insulin infusion systems received regulatory clearances globally, while automated insulin adjustment features increased by 33%, pediatric insulin pump approvals expanded by 21%, and wearable compact devices rose by approximately 27%.

Continuous Subcutaneous Insulin Infusion Market Latest Trends

The Continuous Subcutaneous Insulin Infusion Market is witnessing substantial technological transformation due to increasing demand for automated diabetes management solutions. Nearly 52% of newly approved insulin pumps in 2025 featured hybrid closed-loop capabilities integrated with continuous glucose monitoring systems. More than 47% of diabetic patients using advanced insulin pumps preferred smartphone-controlled interfaces, compared with 31% in 2021. Compact wearable patch pumps gained significant traction, accounting for approximately 38% of total device installations globally. Artificial intelligence integration is becoming a major market trend, with over 36% of next-generation insulin infusion systems supporting predictive insulin dosing algorithms.

Bluetooth-enabled pump connectivity expanded by 44% between 2022 and 2025, improving remote monitoring efficiency for healthcare providers. Pediatric insulin pump adoption also increased significantly, with nearly 28% of insulin-dependent children using continuous insulin infusion devices in developed economies. Disposable patch pumps experienced approximately 24% growth in prescription rates due to reduced tubing complications and simplified usability. Battery efficiency improved by nearly 19% across major manufacturers, while waterproof insulin pump designs represented over 41% of new launches. Additionally, around 58% of endocrinologists globally recommended insulin pump therapy for patients with uncontrolled HbA1c levels exceeding 8%, supporting continuous demand across clinical diabetes management programs.

Continuous Subcutaneous Insulin Infusion Market Dynamics

DRIVER

"Rising prevalence of type 1 and insulin-dependent diabetes"

The increasing incidence of diabetes remains the strongest growth driver for the Continuous Subcutaneous Insulin Infusion Market. Globally, more than 537 million adults were diagnosed with diabetes in 2024, and approximately 9 million individuals suffer from type 1 diabetes. Continuous insulin infusion systems are increasingly prescribed because nearly 72% of type 1 diabetic patients require intensive insulin therapy multiple times daily. Studies indicate that insulin pump therapy can reduce HbA1c levels by 0.5% to 1.2% compared with multiple daily injection methods. More than 61% of endocrinologists in developed economies now prioritize insulin pump therapy for pediatric diabetes management. Automated insulin delivery systems also reduced severe hypoglycemia incidents by nearly 40% in clinical settings. Rising obesity prevalence, which exceeded 16% among adults globally, is further increasing insulin dependence rates, directly supporting demand for advanced insulin infusion technologies.

RESTRAINT

"High device costs and technical complexity"

High acquisition and maintenance costs continue to restrict broader adoption of continuous subcutaneous insulin infusion systems, especially in low-income healthcare markets. Approximately 42% of diabetic patients reported affordability concerns related to insulin pump therapy. Infusion-set replacement every 2 to 3 days increases annual consumable dependency by nearly 120 units per patient. Around 33% of first-time users reported technical difficulties associated with calibration, reservoir replacement, or software synchronization. Device discontinuation rates reached nearly 19% within 2 years due to operational challenges and skin irritation issues. In developing economies, less than 8% of insulin-dependent diabetic patients currently have access to advanced insulin infusion systems due to limited reimbursement infrastructure. Cybersecurity concerns linked to wireless insulin delivery systems also increased by approximately 14% between 2022 and 2025, impacting patient confidence in connected medical devices.

OPPORTUNITY

"Expansion of connected healthcare and wearable diabetes technologies"

The integration of wearable healthcare systems and remote patient monitoring presents significant opportunities for the Continuous Subcutaneous Insulin Infusion Market. More than 58% of diabetes management devices launched after 2023 included cloud-based connectivity features. Smartphone-controlled insulin pumps increased by nearly 45% globally due to rising digital health adoption. Continuous glucose monitor integration expanded across 63% of advanced insulin pump platforms, supporting automated insulin adjustments every 5 minutes. Telehealth consultations for diabetes management rose by approximately 37% after 2022, increasing demand for remotely manageable infusion devices. Emerging markets such as India and China collectively account for more than 150 million diabetic adults, yet insulin pump penetration remains below 5%, creating substantial untapped opportunities. Pediatric diabetes programs in Europe and North America also increased insulin pump reimbursement coverage by nearly 22%, supporting wider adoption among younger patients.

CHALLENGE

"Regulatory compliance and patient training limitations"

Regulatory approvals and patient education remain major challenges for the Continuous Subcutaneous Insulin Infusion Market. Insulin infusion systems require strict safety validation because dosing inaccuracies above 10% can create severe glycemic complications. More than 27% of diabetic patients reported difficulties understanding advanced pump settings during the first 6 months of use. Healthcare providers spend an average of 6 to 10 hours training insulin pump users before therapy stabilization. Product recalls related to software malfunctions increased by nearly 12% between 2021 and 2024. Regulatory approval timelines for automated insulin delivery systems can exceed 18 months across multiple regions. In emerging healthcare systems, fewer than 30% of diabetes clinics possess specialized insulin pump educators. Limited healthcare professional training combined with inconsistent reimbursement policies continues to challenge expansion into rural and underserved diabetic populations globally.

Segmentation Analysis

The Continuous Subcutaneous Insulin Infusion Market is segmented by type and application based on patient preferences, device functionality, and healthcare distribution channels. Normal insulin pumps account for nearly 63% of total device utilization due to their established clinical reliability and programmable insulin delivery capabilities. Patch pumps contribute approximately 37% because of increasing demand for tubeless wearable systems. By application, hospitals represent around 41% of market demand due to specialist diabetes care programs, while retail pharmacies account for nearly 36% driven by outpatient insulin therapy adoption. Other channels, including ambulatory care centers and online distribution networks, collectively contribute approximately 23% of insulin infusion system installations globally.

Download FREE Sample to learn more about this report.

By Type

Normal: Normal insulin pumps dominate the Continuous Subcutaneous Insulin Infusion Market with approximately 63% market share due to widespread clinical acceptance and advanced programmable dosing features. More than 1.2 million patients globally use traditional tethered insulin pumps connected through infusion tubing systems. Around 68% of hospitals and diabetes clinics continue to prioritize normal insulin pumps because of their precise basal and bolus insulin delivery functions. Battery-operated programmable pumps account for over 74% of this category. Advanced normal pumps integrated with continuous glucose monitoring systems increased by nearly 32% between 2022 and 2025.

Patch Pump: Patch pumps represent approximately 37% of the Continuous Subcutaneous Insulin Infusion Market and are experiencing rapid adoption because of tubeless wearable convenience. Nearly 44% of newly diagnosed insulin pump users below age 40 prefer patch pump systems due to mobility benefits and discreet design features. Disposable patch pumps reduced tubing-related complications by approximately 31% in comparative clinical studies. More than 28% of female diabetic patients selected patch pumps because of lightweight wearable compatibility. Waterproof patch pump systems accounted for nearly 39% of recent product launches between 2023 and 2025. Automated patch pumps integrated with smartphone applications increased by approximately 41% globally.

By Application

Hospital: Hospitals account for approximately 41% of the Continuous Subcutaneous Insulin Infusion Market due to increasing inpatient diabetes management programs and specialist endocrinology support. Nearly 63% of newly diagnosed type 1 diabetic patients receive insulin pump recommendations during hospital consultations. More than 72% of tertiary care hospitals in developed countries maintain dedicated diabetes technology departments supporting insulin infusion therapy. Inpatient insulin pump usage reduced severe glycemic events by nearly 27% compared with conventional injection-based treatment methods. Hospitals also conduct over 58% of insulin pump training sessions globally.

Retail Pharmacy: Retail pharmacies contribute approximately 36% of market distribution due to increasing outpatient diabetes treatment demand and prescription refill accessibility. Nearly 61% of insulin infusion consumables, including infusion sets and reservoirs, are distributed through retail pharmacy networks. Community pharmacy insulin pump counseling services increased by approximately 29% between 2021 and 2025. Around 48% of diabetic patients prefer pharmacy-based device procurement because of insurance coordination support and local availability. Retail pharmacies also facilitate over 35% of wearable patch pump sales globally.

Other: Other applications, including ambulatory care centers, home healthcare providers, and online medical distributors, account for approximately 23% of the Continuous Subcutaneous Insulin Infusion Market. Home healthcare insulin pump support services increased by nearly 33% globally between 2022 and 2025. Ambulatory diabetes clinics manage approximately 18% of insulin pump therapy initiation programs due to lower operational costs compared with hospitals. Telemedicine-assisted insulin pump monitoring expanded by over 37%, particularly in rural diabetic populations.

Regional Outlook

The Continuous Subcutaneous Insulin Infusion Market demonstrates strong regional variation driven by diabetes prevalence, reimbursement systems, healthcare infrastructure, and wearable technology adoption. North America holds approximately 44% market share, Europe accounts for nearly 29%, Asia-Pacific contributes around 21%, and Middle East & Africa represent about 6%. Increasing insulin pump penetration, expanding continuous glucose monitoring integration, and rising pediatric diabetes cases continue supporting regional market expansion globally.

Download FREE Sample to learn more about this report.

North America

North America leads the Continuous Subcutaneous Insulin Infusion Market with nearly 44% share of global insulin pump installations, supported by advanced diabetes management infrastructure and strong adoption of automated insulin delivery systems. The United States contributes approximately 85% of regional demand, driven by more than 38 million diagnosed diabetic patients and nearly 1.9 million individuals living with type 1 diabetes. Around 550,000 insulin pump users are currently active across the U.S., while hybrid closed-loop systems account for approximately 41% of newly prescribed insulin infusion devices. Canada contributes nearly 11% of regional market demand due to rising pediatric diabetes management programs and expanded public reimbursement policies.

More than 73% of endocrinologists across North America recommend insulin pump therapy for patients requiring intensive insulin treatment. Continuous glucose monitoring integration exceeds 67% among insulin pump users, improving glycemic control and reducing severe hypoglycemia episodes by approximately 30%. Pediatric insulin pump adoption surpassed 30% among children with type 1 diabetes treated in specialized endocrinology centers. Patch pump utilization increased by approximately 29% between 2022 and 2025 because of growing demand for wearable and tubeless diabetes management systems. Retail pharmacies account for nearly 39% of insulin infusion consumable distribution, while hospitals support more than 58% of insulin pump initiation and patient education programs across the region.

Europe

Europe accounts for approximately 29% of the Continuous Subcutaneous Insulin Infusion Market due to established reimbursement frameworks, increasing diabetes awareness, and high penetration of advanced diabetes technologies. Germany, the United Kingdom, France, and Italy collectively contribute nearly 68% of regional insulin pump installations. More than 61 million adults in Europe are living with diabetes, while pediatric type 1 diabetes incidence continues to increase by approximately 3% annually in several countries. Northern European nations demonstrate particularly high insulin pump adoption, with approximately 34% of insulin-dependent diabetic patients using continuous insulin infusion systems.

Germany represents nearly 22% of Europe’s insulin pump demand due to strong healthcare technology integration and specialized endocrinology centers. Public reimbursement systems in Western Europe cover more than 70% of insulin pump therapy costs, supporting wider accessibility among diabetic patients. Hybrid closed-loop insulin delivery systems increased adoption by approximately 26% between 2022 and 2025. Patch pumps account for nearly 31% of insulin infusion installations across Europe because of increasing preference for wearable diabetes technologies. More than 57% of diabetes clinics use integrated continuous glucose monitoring with insulin pumps for automated insulin adjustments. Pediatric insulin pump adoption exceeded 28% in Scandinavian countries, while hospital endocrinology departments manage approximately 46% of regional insulin pump therapy initiations.

Asia-Pacific

Asia-Pacific represents approximately 21% of the Continuous Subcutaneous Insulin Infusion Market and contains the world’s largest diabetic population base. China and India together account for more than 230 million diabetic adults, although insulin pump penetration remains below 5%, creating substantial growth potential. Japan, South Korea, and Australia maintain higher insulin pump adoption rates due to advanced healthcare infrastructure and broader reimbursement availability. Japan alone contributes approximately 29% of regional insulin pump utilization. Wearable patch pumps account for nearly 41% of newly installed insulin infusion systems in urban healthcare facilities across developed Asia-Pacific countries.

Smartphone-integrated insulin pumps increased by approximately 38% between 2022 and 2025 due to growing digital healthcare adoption. Pediatric diabetes management programs expanded insulin pump access by nearly 19% in metropolitan hospitals across China and India. More than 48% of diabetic patients in the region continue using traditional insulin injection therapies, creating strong opportunities for insulin infusion manufacturers. Government diabetes screening initiatives increased by approximately 23% after 2023, supporting earlier diagnosis and insulin therapy adoption. Urban hospitals account for nearly 52% of insulin pump installations because of specialized endocrinology services. Online healthcare platforms contribute approximately 17% of insulin infusion consumable distribution across Asia-Pacific markets, supporting remote diabetes management and device accessibility.

Middle East & Africa

Middle East & Africa account for approximately 6% of the Continuous Subcutaneous Insulin Infusion Market, supported by rising diabetes prevalence, urbanization, and expanding healthcare investments. Gulf Cooperation Council countries contribute nearly 58% of regional insulin pump demand because of higher healthcare spending and advanced diabetes treatment programs. Saudi Arabia and the United Arab Emirates report adult diabetes prevalence rates exceeding 16%, among the highest globally. More than 24 million adults across the Middle East are currently living with diabetes, while obesity prevalence surpassed 27% in several Gulf nations. Insulin pump adoption increased by approximately 18% between 2022 and 2025 due to improved reimbursement programs, specialist diabetes clinics, and growing awareness regarding automated insulin delivery systems.

Hybrid closed-loop technologies account for nearly 22% of premium insulin pump installations across major urban hospitals. Patch pump adoption also increased by approximately 14% because of increasing demand for wearable and discreet diabetes management solutions. South Africa contributes approximately 19% of insulin pump demand across Africa due to comparatively stronger healthcare infrastructure and diabetes awareness initiatives. Hospital-based diabetes care programs manage more than 61% of insulin infusion therapy initiation cases in the region. Retail pharmacy penetration remains below 28%, limiting accessibility in rural communities. Telemedicine-supported diabetes monitoring expanded by approximately 21% after 2023, improving insulin pump support for remote patient populations.

List of Top Continuous Subcutaneous Insulin Infusion Companies

• Medtronic – Holds approximately 38% global market share with more than 300,000 active insulin pump users and over 100 countries served through integrated diabetes management systems.
• Insulet Corp – Accounts for nearly 21% market share globally, with patch pump systems representing approximately 80% of the company’s diabetes device installations worldwide.

Investment Analysis and Opportunities

The Continuous Subcutaneous Insulin Infusion Market is attracting strong investment activity due to rising diabetes prevalence and increasing demand for automated insulin delivery technologies. More than 48% of venture capital investments in diabetes devices during 2024 targeted wearable insulin management systems. Artificial intelligence integration funding increased by approximately 36% between 2022 and 2025. Companies developing hybrid closed-loop systems accounted for nearly 41% of medical technology partnership agreements globally. North America represents approximately 44% of global investment concentration because of high insulin pump adoption and established reimbursement frameworks. Asia-Pacific is emerging as a major investment destination, supported by over 230 million diabetic adults in China and India combined. Manufacturing localization initiatives increased by approximately 27% in Asia to reduce supply chain dependency and production costs. Patch pump innovation projects account for nearly 33% of current insulin infusion research pipelines. More than 52% of healthcare investors prioritize smartphone-connected insulin delivery systems with remote monitoring capabilities. Pediatric diabetes management remains another investment opportunity, as insulin pump utilization among children increased by approximately 22% globally after 2023. Telehealth integration partnerships also expanded by nearly 31%, creating opportunities for connected insulin infusion ecosystems supporting real-time glucose management and automated insulin optimization.

New Product Development

New product development within the Continuous Subcutaneous Insulin Infusion Market is focused on miniaturization, automation, connectivity, and patient comfort improvements. More than 54% of insulin pumps launched after 2023 included smartphone integration features. Automated insulin adjustment algorithms capable of updating dosing every 5 minutes are now integrated into approximately 43% of advanced systems. Tubeless patch pump innovation increased significantly, with nearly 39% of newly introduced products designed for waterproof and disposable use. Battery life improvements reached approximately 19% across next-generation wearable insulin pumps. Artificial intelligence-supported predictive glucose alerts were incorporated into over 34% of product launches between 2023 and 2025.

Pediatric-friendly insulin pumps with lightweight designs below 30 grams represented approximately 18% of recent device introductions. Bluetooth-enabled insulin infusion systems accounted for nearly 47% of all newly approved devices globally. Companies are also developing extended wear infusion sets capable of functioning for up to 7 days, reducing replacement frequency by nearly 57% compared with standard infusion systems. Remote software update capability expanded by approximately 26%, improving cybersecurity compliance and device maintenance efficiency. Integration with cloud-based diabetes management applications increased across 51% of new insulin pump platforms introduced during 2025.

Five Recent Developments (2023-2025)

• 2025: Tandem Diabetes Care commercially launched Control-IQ+ technology in the U.S., extending automated insulin delivery to patients aged 2 years and older with type 1 diabetes and adults with type 2 diabetes.
• 2025: Medtronic advanced its MiniMed ecosystem by introducing compatibility plans with Abbott’s 15-day Instinct CGM sensor, enhancing integrated insulin pump functionality.
• 2024: Abbott and Medtronic announced a strategic collaboration to develop glucose sensors designed for integration with Medtronic automated insulin delivery systems.
• 2024: Insulet expanded the Omnipod 5 platform with broader automated insulin delivery capabilities and additional regulatory clearances supporting use in younger patient populations.
• 2023: Tandem Diabetes Care enabled integration of the Dexcom G7 continuous glucose monitor with the t X2 insulin pump through a remote software update for eligible U.S. users.

Report Coverage of Continuous Subcutaneous Insulin Infusion Market

The Continuous Subcutaneous Insulin Infusion Market Report provides extensive analysis of insulin pump technologies, diabetes prevalence trends, patient adoption patterns, competitive positioning, and regional demand distribution. The report evaluates more than 20 countries across North America, Europe, Asia-Pacific, and Middle East & Africa. Over 50 statistical indicators related to insulin pump usage, wearable healthcare penetration, and diabetes treatment infrastructure are included. The report analyzes segmentation by type, including normal insulin pumps and patch pumps, which collectively account for 100% of market installations. Application analysis covers hospitals, retail pharmacies, ambulatory care centers, and home healthcare environments.

Approximately 63% of market assessment focuses on conventional programmable insulin pumps, while patch pump innovation trends represent nearly 37% of analyzed device categories. Technology assessment includes hybrid closed-loop systems, Bluetooth-enabled pumps, artificial intelligence-supported insulin delivery, and continuous glucose monitor integration. More than 49% of current market demand is linked to automated insulin adjustment capabilities. The report also evaluates pediatric insulin pump adoption, telemedicine integration, reimbursement frameworks, and wearable medical device expansion trends. Competitive profiling covers major manufacturers representing over 71% of global insulin pump penetration, while regional analysis evaluates diabetic population distribution exceeding 537 million adults worldwide.